clinical trial · NCT05809908
Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
Cerecin·phase3·not yet recruiting·n = 535
Alzheimer DiseaseTricaprilinPlacebo
brief summary
The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, global function, activities of daily living, resource utilisation, safety, and tolerability, in participants with mild to moderate AD dementia. This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants.
started
Jun 1, 2026
primary completion
Dec 1, 2028
completion
Jan 1, 2029
last updated
Nov 25, 2025
official title
A Phase 3, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-OLE-01-VA in Participants With Mild to Moderate Alzheimer's Disease Dementia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol